Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Bearish
5
Neutral
6
Bullish
3
Bearish
7
Neutral
10
Bullish
29
Bearish
2
Neutral
4
Bullish
26
Discovery themes featuring this stock
Rubicon Research Limited is a pharmaceutical company specializing in research, development, and manufacturing of specialty drugs and medical formulations for regulated markets, especially the US.
The company experienced significant financial growth, with revenue up by 51.7% and profit after tax increasing by 91.2% year-over-year in Q3 FY26. These results reflect its broad-based product revenue strategy.
Focus on specialty, drug-device combinations and complex generics is bolstered by extensive manufacturing capabilities in Maharashtra and a strategic acquisition of Pithampur facility from Alkem Laboratories to enhance capacity.
Rubicon's diversified portfolio, with approvals for unique and high-demand products like nasal sprays, showcases its innovation-driven model and commitment to addressing unmet medical needs.
The company's efficient capital deployment for R&D and operations is evidenced by high R&D productivity, with increasing returns on investment leading to strong growth prospects.
Pharmaceuticals & Biotechnology
Pharmaceuticals
25,837 Cr
Low Risk
104.7
37.2
1.6
20.1
1,589.00
571.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1886.85 | 30,311 Cr | 106.72 | 6.14 | 0.00 | 5.75 | 7.39 | 2.31 | ||
3309.05 | 27,579 Cr | 71.41 | 16.68 | 0.07 | 21.54 | 28.77 | 19.52 | ||
1300.30 | 27,347 Cr | 77.04 | 11.01 | 0.00 | 14.05 | 18.23 | 9.62 | ||
1533.95 | 25,837 Cr | 104.71 | 20.05 | 0.10 | 19.14 | 22.56 | 10.60 | ||
193.40 | 25,569 Cr | — | 3.13 | 0.00 | -3.58 | 2.58 | -1.81 | ||
18859.80 | 24,345 Cr | 67.42 | 12.99 | 0.18 | 19.42 | 23.57 | 12.42 | ||
4720.55 | 21,456 Cr | 28.28 | 5.11 | 1.60 | 17.19 | 23.02 | 14.68 | ||
| Median: 7 Co. | — | 1886.85 | 25,837 Cr | 74.22 | 11.01 | 0.07 | 17.19 | 22.56 | 10.60 |
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Rubicon Research Ltd (RUBICON) is currently trading at 1,533.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Rubicon Research Limited is a pharmaceutical company specializing in research, development, and manufacturing of specialty drugs and medical formulations for regulated markets, especially the US. The company experienced significant financial growth, with revenue up by 51.7% and profit after tax increasing by 91.2% year-over-year in Q3 FY26. These results reflect its broad-based product revenue strategy. Focus on specialty, drug-device combinations and complex generics is bolstered by extensive manufacturing capabilities in Maharashtra and a strategic acquisition of Pithampur facility from Alkem Laboratories to enhance capacity. Rubicon's diversified portfolio, with approvals for unique and high-demand products like nasal sprays, showcases its innovation-driven model and commitment to addressing unmet medical needs. The company's efficient capital deployment for R&D and operations is evidenced by high R&D productivity, with increasing returns on investment leading to strong growth prospects.
Over the past 52 weeks, Rubicon Research Ltd has traded between a low of ₹571.00 and a high of ₹1,589.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Rubicon Research Ltd has a market capitalization of approximately 25,836.92. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Rubicon Research Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 104.71 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 25,836.92 Cr, Rubicon Research Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Rubicon Research Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Rubicon Research Ltd is 104.71. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Rubicon Research will acquire an 85% equity stake in Arinna Lifesciences.
Scheme of Arrangement
Rubicon Research Ltd files scheme to merge its wholly owned subsidiary Kia Health Tech Private Limited into Rubicon. Board approved the scheme on July 20, 2026; relies on SEBI exemption and involves no share issuance.
Scheme of Arrangement
Rubicon Research Ltd filed a Scheme to merge its wholly owned subsidiary Kia Health Tech Pvt Ltd into the company; Board approved on July 20, 2026. Merger falls under SEBI Paragraph 4 exemption, involves no share issuance and is subject to approvals.
Scheme of Arrangement
Rubicon Research Ltd disclosed Board approval (20-Jul-2026) of a scheme to merge its wholly owned subsidiary Kia Health Tech Pvt Ltd into Rubicon. Merger is subject to statutory approvals, involves no share issuance and filed under SEBI exemption.
Merger/Acquisition
Rubicon Research Ltd announced on 22 July 2026 that its wholly-owned US subsidiary AdvaGen acquired a manufacturing facility in East Brunswick, NJ from InvaTech for an enterprise value of USD 2.9m; site taken over on 21 July 2026.
Merger/Acquisition
Rubicon Research Ltd's subsidiary AdvaGen acquired a manufacturing facility in East Brunswick, NJ from InvaTech for an enterprise value of USD 2.9M; takeover on 21-07-2026. Site USFDA-inspected; manufacturing to start in 2027 after QMS setup.
